Market Place
Sourcing Support
Abivax: 25mg Obefazimod Shows 2-Year Success In Colitis Study
03 Oct 2024 //
GLOBENEWSWIRE
Abivax Enrolls 1st Patient In ENHANCE-CD Trial For Crohn`s Disease
03 Oct 2024 //
GLOBENEWSWIRE
Abivax To Present Obefazimod Abstracts At UEG Week 2024
26 Sep 2024 //
GLOBENEWSWIRE
Abivax Updates On UC Combination Therapy Program Strategy
25 Sep 2024 //
GLOBENEWSWIRE
Publication of an expert article in JCC on obefazimod as promising therapeutic
02 May 2023 //
PHARMIWEB
Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod
17 Apr 2023 //
ACCESSWIRE
Abivax Publishes Novel Data with Respect to Obefazimod’s Mechanism of Action
05 Jan 2023 //
ACCESSWIRE
Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod
20 Dec 2022 //
ACCESSWIRE
First US Patient Enrolled in Global Phase 3 Program with Obefazimod
11 Oct 2022 //
ACCESSWIRE
Abivax Phase 2b Study Results of Obefazimod (ABX464) in Ulcerative Colitis
05 Sep 2022 //
ACCESSWIRE
Abivax raises $49M to cross the PhIII finish line for ulcerative colitis drug
02 Sep 2022 //
ENDPTS
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.